The emerging role of PI3K inhibitors for solid tumour treatment and beyond
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://www.nature.com/articles/s41416-023-02221-1.pdf
Reference63 articles.
1. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. https://doi.org/10.1126/science.1096502
2. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, et al. A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell. 2017;31:820.e3–32.e3. https://doi.org/10.1016/j.ccell.2017.04.013
3. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13. https://doi.org/10.1038/nm.4333
4. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway. Nat Rev Clin Oncol. 2018;15:273–91. https://doi.org/10.1038/nrclinonc.2018.28
5. Petroni G, Buque A, Zitvogel L, Kroemer G, Galluzzi L. Immunomodulation by targeted anticancer agents. Cancer Cell. 2021;39:310–45. https://doi.org/10.1016/j.ccell.2020.11.009
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis;European Journal of Pharmacology;2024-11
2. Identification of activating somatic mutations in the <i>PIK3CA</i> gene in breast tumors and determination of their minimal set for clinical diagnostic testing;Almanac of Clinical Medicine;2024-09-10
3. Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential;Molecules;2024-09-09
4. Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations;Hereditary Cancer in Clinical Practice;2024-08-19
5. Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example;Frontiers in Pharmacology;2024-08-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3